2632305-36-1
2632305-36-1
Chemical Structure
ARD-1676
- CAS No.: 2632305-36-1
- Formula:C44H46ClN7O5
- Molecular Weight:788.33
InChIKey: GAXWAKXJBZHVQF-ZVENJKCTSA-N
SMILES: C[C@H]1CC2(CN1C3=CC=C(C(Cl)=C3)C#N)CCN(CC2)C4=CC=C(C=C4)C(N5CCC(CC5)CN6CC7=C(C6)C=C8C(N(C(C8=C7)=O)C9CCC(NC9=O)=O)=O)=O
Biological Activity: ARD-1676 is an orally active androgen receptor (AR) PROTAC degrader. ARD-1676 induces proteasomal degradation of AR, inhibits AR-regulated gene expression, suppresses cell growth, reduces AR protein levels and inhibits tumor growth in in vivo models. ARD-1676 can be used in studies related to AR+ human prostate cancer and spinal bulbar muscular atrophy[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ARD-1676 | 98.21% | ARD-1676 is an orally active androgen receptor (AR) PROTAC degrader. ARD-1676 induces proteasomal degradation of AR, inhibits AR-regulated gene expression, suppresses cell growth, reduces AR protein levels and inhibits tumor growth in in vivo models. ARD-1676 can be used in studies related to AR+ human prostate cancer and spinal bulbar muscular atrophy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Xiang W, et al. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer. Journal of medicinal chemistry. 2023 Sep 28;66(18):13280-13303. [Content Brief]
- [2]. Sangotra A, et al. PROTACs therapeutically target the polyglutamine androgen receptor in spinal and bulbar muscular atrophy models. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2025 Oct;22(6):e00732. [Content Brief]
